Rachel Thorn

Partner
Full contact info

Experience

Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million

July 11, 2019

Jazz Pharmaceuticals in its acquisition of Redx Pharma's (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors. Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization. Jazz will pay Redx an upfront payment of $3.5 million. Redx is eligible to receive up to $203 million in development, regulatory and commercial milestone payments and incremental tiered royalties in mid-single digit percentage, based on any future net sales.

Related contacts

Marya Postner
Partner, Palo Alto
Geoffrey Spolyar
Partner, Boston
John Clark
Partner, London
John Wilkinson
Partner, London
Barbara Borden
Partner, San Diego
Dr. Jon Cousin
Partner, Washington, DC
Rachel Thorn
Partner, New York

Related Practices & Industries

X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics

September 2, 2019

Cooley advised X4 Pharmaceuticals in its exclusive license agreement with Abbisko Therapeutics granting Abbisko exclusive rights to develop and commercialize maxorixafor in combination with checkpoint inhibitors or other agents in oncology indications in China, Taiwan, Hong Kong and Macau.

Related contacts

Geoffrey Spolyar
Partner, Boston
Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Santa Monica

Related Practices & Industries

Forty Seven in its Exclusive License Agreement with Ono Pharmaceutical

September 2, 2019

Cooley advised Forty Seven in its exclusive license agreement with Ono Pharmaceutical granting Ono the rights to develop and commercialize anti-CD47 antibody products in Japan, South Korea, Taiwan and ASEAN countries. Under the terms of the agreement, Forty Seven received $16 million upfront, plus up to $104 million in milestone payments and tiered royalties on net sales at percentages ranging from mid-single digits to twenty.

Related contacts

Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado

Related Practices & Industries

GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals

September 2, 2019

Cooley advised GENFIT SA in its licensing and collaboration agreement with Terns Pharmaceuticals. Terns will have the rights to develop and commercialize elafibranor, GENFIT’s proprietary compound, in Greater China. Under the terms of the agreement, GENFIT received an upfront payment from Terns of $35 million and will be eligible to receive up to $193 million in potential clinical, regulatory and commercial milestone payments.

Related contacts

Geoffrey Spolyar
Partner, Boston
Christina Zhang
Partner, Shanghai
Rachel Thorn
Partner, New York
Aaron Pomeroy
Partner, Colorado
Rick Jantz
Associate, Santa Monica

Related Practices & Industries

I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment

September 10, 2020

Cooley advised I-Mab on its global collaboration agreement with AbbVie for the development and commercialization of lemzoparlimab, one of I-Mab’s leading drug candidates, for the treatment of multiple cancers. Lawyers Lila Hope and Jennifer Raab led the Cooley team advising I-Mab on the agreement. 

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Amanda Pacheco
Associate, Palo Alto
Jeffrey J. Tolin
Partner, New York
Rachel Thorn
Partner, New York
Andrew Epstein
Special Counsel, Seattle

Related Practices & Industries

View more

Admissions and credentials

New York

Rankings and accolades

Who’s Who Legal: Recommended – Arbitration (2024)

Chambers USA: International Arbitration: Counsel – Nationwide (2021 – 2024)

The Legal 500 US: International Arbitration

Benchmark Litigation: Future Star (2014)

Global Arbitration Review: Top 45 Under 45 (2011)